Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131720 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL29277815 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL1131717 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL1131055 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL5106131 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL30777230 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL31136363 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL6097487 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL21782566 | 1.00 | ANPEP (0.50) | ANPEPIDO1SLC18A3PDPK1PLAU | |
| SCHEMBL6338202 | 0.89 | IDO1 (0.51) | ANPEPIDO1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288553-A1 | Antimicrobial Compositions and Uses for Treatment of Clostridioides difficile, Mycobacterium tuberculosis, and Enterococcus faecalis Infection | THE UNIVERSITY OF TOLEDO | 2025-09-18 | — | — | US | disclosed |
| CN-120077042-A | 3A,4,5, 6-tetrahydro-1H-pyrazolo [3,4-C ] pyridin-7 (7 AH) -one derivatives as factor XIIa inhibitors | 卡尔维斯塔制药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025096589-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-110831926-B | Tetrahydronaphtyl urea derivatives | 持田制药株式会社 | 2023-11-21 | — | — | CN | disclosed |
| WO-2023215619-A2 | ANTIMICROBIAL COMPOSITIONS AND USES FOR TREATMENT OF CLOSTRIDIOIDES DIFFICILE, MYCOBACTERIUM TUBERCULOSIS, AND ENTEROCOCCUS FAECALIS INFECTION | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288553-A1 | Antimicrobial Compositions and Uses for Treatment of Clostridioides difficile, Mycobacterium tuberculosis, and Enterococcus faecalis Infection | VDR, CYP2R1, PTH1R | ANPEP 2192/4885IDO1 1625/4885SLC18A3 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.